美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

全球合伙

48.91

-1.8600-3.66%

成交量：3.66万

成交额：179.68万

市值：16.47亿

市盈率：20.29

高：50.98

开：50.98

低：48.14

收：50.77

数据加载中...

总览公司新闻公告

Global Partners盘中异动急速下跌5.18%

GLP-1竞争新动向：礼来后来居上？

医药行业周报：礼来首个小分子口服GLP-1药物3期临床研究成功有望改变减重药物格局

平安证券股份有...

医药行业周报：本周医药下跌0.4% 人民时评要求保证药企药店利润空间礼来口服GLP-1治疗糖尿病研发成功

上海申银万国证...

诺和诺德、礼来“二王争霸”，国产GLP-1抢夺新适应症，恒瑞医药们不想只做减肥神药

两大跨国巨头称霸GLP-1市场，国产减肥药的机会在哪？

减重GLP-1制剂将进入每日一次“口服”时代礼来回应：已在准备产能计划

每日经济新闻

翰宇药业：全资子公司替尔泊肽原料药获韩国MFDS受理

【翰宇药业：全资子公司替尔泊肽原料药获韩国MFDS受理】翰宇药业公告，全资子公司翰宇药业（武汉）有限公司的替尔泊肽原料药获得韩国食品药品安全厅（MFDS）的审批受理。替尔泊肽是一种新型GLP-1/GIP双受体激动剂，适用于2型糖尿病、肥胖症等治疗。该药品的受理将完善公司产品版图，提升公司竞争力，有望对公司业绩增长和行业地位产生积极影响。

礼来预计年底前向全球监管机构提交orforglipron用于体重管理的上市申请

GLP-1减肥药市场博弈：礼来领航突破、辉瑞折戟沉沙，创新战如何取胜？

21世纪经济报道

礼来首个小分子口服GLP-1药物3期临床研究成功有望颠覆减重药物格局

美联邦法官裁定谷歌非法垄断部分广告技术市场；礼来首款GLP-1口服药报告积极三期试验结果丨全球科技早参

每日经济新闻

太平洋医药日报：礼来口服GLP-1受体激动剂ORFORGLIPRON三期临床成功

太平洋证券股份...

礼来(LLY.US)口服小分子GLP-1R激动剂III期研究成功

【通化东宝利拉鲁肽注射液获哥伦比亚GMP证书】近日，通化东宝与合作伙伴科兴生物制药股份有限公司携手的出海产品—利拉鲁肽注射液，正式获得哥伦比亚国家食品药品监督管理局颁发的GMP证书，为后续该产品在哥伦比亚的获批上市，以及拉美其他国家的市场准入打下坚实基础。利拉鲁肽注射液作为GLP-1受体激动剂，凭借其降糖、减重及心血管保护的多重疗效，已成为全球糖尿病治疗的一线药物，受到患者的广泛认可。

下一代减肥药：跨越GLP-1巅峰

辉瑞再终止GLP-1药物开发！罗氏、艾伯维等弯道超车？

医药经济报

1名受试者出现肝损伤，辉瑞终止一款口服减肥药临床开发，死磕小分子GLP-1

辉瑞又双叒叕放弃一款口服 GLP-1，肥胖管线仅剩 1 款药物

Insight数据库

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/GLP/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","market":"US","secType":"STK","nameCN":"全球合伙","latestPrice":48.91,"timestamp":1745265600000,"preClose":50.77,"halted":0,"volume":36612,"delay":0,"floatShares":25096277,"shares":33668256,"eps":2.41,"marketStatus":"盘前交易","change":-1.86,"latestTime":"04-22 07:19:58 EDT","open":50.98,"high":50.98,"low":48.14,"amount":1796750.00928,"amplitude":0.055939,"askPrice":63.5,"askSize":100,"bidPrice":36.22,"bidSize":100,"shortable":3,"etf":0,"ttmEps":2.41,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1127966400000,"exchange":"NYSE","adjPreClose":48.91,"postHourTrading":{"tag":"盘后","latestPrice":48.91,"preClose":48.91,"latestTime":"19:06 EDT","volume":30,"amount":1463.275,"timestamp":1745276819507},"volumeRatio":1.151936566964889,"impliedVol":0.5142,"impliedVolPercentile":0.751},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","floatShares":25096277,"roa":"4.19%","roe":"14.20%","lyrEps":2.44604,"volumeRatio":1.151936566964889,"shares":33668256,"dividePrice":2.96,"high":50.98,"amplitude":0.055939,"preClose":50.77,"low":48.14,"week52Low":37.0034,"pbRate":"2.57","psRate":"0.10","week52High":60,"institutionHeld":0.407,"latestPrice":48.91,"eps":2.41,"divideRate":0.060519,"volume":36612,"delay":0,"ttmEps":2.41,"open":50.98,"prevYearClose":46.55,"prevWeekClose":50.77,"prevMonthClose":53.38,"prevQuarterClose":53.38,"fiveDayClose":48.21,"twentyDayClose":53.11,"sixtyDayClose":51.67},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GLP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529339385","title":"Global Partners盘中异动 急速下跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529339385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529339385?lang=zh_cn&edition=fundamental","pubTime":"2025-04-22 01:55","pubTimestamp":1745258158,"startTime":"0","endTime":"0","summary":"北京时间2025年04月22日01时55分，Global Partners股票出现异动，股价急速下挫5.18%。Global Partners股票所在的油气中游产业行业中，整体跌幅为4.24%。其相关个股中，Imperial Petroleum Inc (Marshall Is 8.75% Cum Red Perp Pfd A、BPT信托、Imperial Petroleum Inc.涨幅较大，Scorpio Tankers Inc.、Viper Energy, Inc.、Kinetik Holdings Inc.较为活跃，换手率分别为0.57%、0.50%、0.49%，振幅较大的相关个股有Cbl International Limited、Robin Energy Ltd.、Dynagas Lng Partners Lp，振幅分别为15.79%、14.03%、9.44%。Global Partners公司简介：Global Partners LP是一家作为中游物流和营销公司的有限合伙企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422015558973fa34a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422015558973fa34a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4590","GLP","BK4144"],"gpt_icon":0},{"id":"2529177858","title":"GLP-1竞争新动向：礼来后来居上？","url":"https://stock-news.laohu8.com/highlight/detail?id=2529177858","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529177858?lang=zh_cn&edition=fundamental","pubTime":"2025-04-21 11:05","pubTimestamp":1745204734,"startTime":"0","endTime":"0","summary":"尽管GLP-1火遍全球，但实际上，现在还没有任何一款GLP-1口服版药物获批了减重适应症。GLP-1尽管看来已经接近完美，但依然有很大的不足。口服药就完全规避了以上所有劣势，从诺和诺德、礼来的开发劲头可以看出，今后GLP-1药物的竞争会逐渐从注射剂转到口服制剂上。口服减肥GLP-1可能会成为礼来反超的一张王牌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421110753a4606b12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421110753a4606b12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0114720955.EUR","LU0882574055.USD","LU2063271972.USD","LU2471134523.USD","LU2237443465.HKD","LU1291159041.SGD","SG9999001176.USD","SG9999014906.USD","LU0256863902.USD","LU2471134796.USD","LU2552382132.HKD","LU0094547139.USD","LU0096364046.USD","LU1551013342.USD","LU1868837136.USD","LU2361044949.HKD","LU0122379950.USD","LU1983299246.USD","NVO","LU2237443895.HKD","LU1868836914.USD","LU1868837300.USD","SG9999014914.USD","LU2461242641.AUD","LU1551013425.SGD","LU1988902786.USD","LU0006306889.USD","IE00BJT1NW94.SGD","LU1069344957.HKD","LU1917777945.USD","LU0471298777.SGD","LLY","LU1548497426.USD","LU0672654240.SGD","BK4007","IE00BJJMRZ35.SGD","LU2324357040.USD","LU1868836591.USD","SG9999015945.SGD","IE00B1BXHZ80.USD","SGXZ51526630.SGD","GLP","LU2237438978.USD","SG9999001176.SGD","LU1127390331.HKD","LU2491049909.HKD","LU1974910355.USD","LU1366192091.USD","LU0943347566.SGD","LU2471134952.CNY","LU2112291526.USD"],"gpt_icon":1},{"id":"2528386165","title":"医药行业周报：礼来首个小分子口服GLP-1药物3期临床研究成功 有望改变减重药物格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2528386165","media":"平安证券股份有...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528386165?lang=zh_cn&edition=fundamental","pubTime":"2025-04-20 00:00","pubTimestamp":1745078400,"startTime":"0","endTime":"0","summary":"行业观点礼来首个小分子口服GLP-1药物3期临床研究成功，有望改变减重药物格局4月17日，全球制药巨头礼来公司公布了3期临床研究ACHIEVE-1的积极顶线结果，该研究评估了Orforglipron与安慰剂相比，在患有2型糖尿病和仅通过饮食和运动控制不足的成人中的安全性和有效性。鉴于患者在研究结束时尚未达到体重平台期，可能表明尚未实现完全减重。公司目前也在研究Orforglipron对非糖尿病患者的减重效果。若获批，Orforglipron将成为第二款在美国上市的GLP-1口服药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250420221112973e6626&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250420221112973e6626&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0882574139.USD","LU1280957306.USD","LU1917777945.USD","IE00BK4W5L77.USD","BK4581","LU0456855351.SGD","LU1989771016.USD","LU1093756168.USD","LU1720051108.HKD","BK4585","LU1868836757.USD","LU1983299246.USD","LU2023250504.SGD","LU0097036916.USD","LU2461242641.AUD","SGXZ57979304.SGD","IE00B1BXHZ80.USD","LU1814569148.SGD","LU0708995401.HKD","LU2237443978.SGD","LLY","LU1988902786.USD","LU2491049909.HKD","LU0820561909.HKD","LU1232071149.USD","LU1551013342.USD","SG9999001176.USD","LU0094547139.USD","IE0009355771.USD","GLP","LU0471298694.HKD","IE00BJJMRZ35.SGD","LU0689472784.USD","LU0203201768.USD","LU2361044865.SGD","SGXZ99366536.SGD","LU0079474960.USD","LU0672654240.SGD","LU2552382215.SGD","LU2471134796.USD","LU1291159041.SGD","LU2750360641.GBP","LU0061475181.USD","SG9999017495.SGD","LU0203202063.USD","LU2237443895.HKD","LU2237443549.SGD","IE00BJLML261.HKD","LU1868837136.USD","LU0096364046.USD"],"gpt_icon":1},{"id":"2528003866","title":"医药行业周报：本周医药下跌0.4% 人民时评要求保证药企药店利润空间 礼来口服GLP-1治疗糖尿病研发成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2528003866","media":"上海申银万国证...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528003866?lang=zh_cn&edition=fundamental","pubTime":"2025-04-20 00:00","pubTimestamp":1745078400,"startTime":"0","endTime":"0","summary":"礼来口服GLP-1 治疗糖尿病研发成功：4 月17 日，礼来宣布首个小分子口服GLP-1RA药物Orforglipron 3 期临床研究成功，ACHIEVE-1 取得了积极的顶线结果。Orforglipron 成为了首个成功完成3 期试验、对饮食或饮水不加以限制的口服小分子GLP-1 受体激动剂。礼来预计将在今年年底前向全球监管机构提交Orforglipron 用于体重管理的上市申请，预计于2026 年提交其用于治疗2 型糖尿病的上市申请。要求国会山调整IRA 药品谈判，旨在进一步降低处方药价格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042021145194dbdd41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042021145194dbdd41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0689472784.USD","LU0708995401.HKD","LU1917777945.USD","LU2361044949.HKD","LLY","LU0109391861.USD","LU0058720904.USD","IE00BK4W5M84.HKD","BK4533","GLP","LU0820561909.HKD","LU1093756325.SGD","LU2211815571.USD","LU1868836914.USD","LU2491050154.USD","SG9999015978.USD","SG9999013999.USD","IE00BK4W5L77.USD","LU1061106388.HKD","LU1814569148.SGD","LU1551013425.SGD","SGXZ81514606.USD","LU1623119135.USD","LU2461242641.AUD","LU1868836757.USD","LU0882574055.USD","BK4534","LU0354030438.USD","IE00B4R5TH58.HKD","LU0061475181.USD","LU0079474960.USD","SGXZ57979304.SGD","LU2265009873.SGD","LU0820561818.USD","LU2552382215.SGD","SGXZ51526630.SGD","LU2237443978.SGD","LU1548497426.USD","LU2089984988.USD","LU2471134879.HKD","LU0882574139.USD","LU1366192091.USD","LU1064131342.USD","IE0002141913.USD","LU2237443382.USD","BK4590","LU2264538146.SGD","LU1868837300.USD","LU0385154629.USD","IE00BJJMRZ35.SGD"],"gpt_icon":1},{"id":"2528107268","title":"诺和诺德、礼来“二王争霸”，国产GLP-1抢夺新适应症，恒瑞医药们不想只做减肥神药","url":"https://stock-news.laohu8.com/highlight/detail?id=2528107268","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528107268?lang=zh_cn&edition=fundamental","pubTime":"2025-04-19 17:46","pubTimestamp":1745055988,"startTime":"0","endTime":"0","summary":"GLP-1（胰高血糖素样肽-1）类药物的适应症不只停留在糖尿病与减重领域，赛道中的玩家们正在加速向其他代谢性疾病及神经系统等更广阔的领域扩围。4月14日，药物临床试验登记与信息公示平台官网显示，信达生物（01801.HK）登记了一项评估玛仕度肽（IBI362）在患有中重度阻塞性睡眠呼吸暂停且肥胖的受试者中有效性和安全性的Ⅲ期临床试验（GLORY-OSA）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504193381946449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0096364046.USD","LU0203202063.USD","LU1069344957.HKD","LU2552382215.SGD","LU0198837287.USD","IE00BJT1NW94.SGD","LU2237438978.USD","LU2264538146.SGD","BK4590","LU0238689110.USD","LU1093756168.USD","LU1988902786.USD","LU1023059063.AUD","SG9999014914.USD","LU0256863811.USD","LU1551013425.SGD","BK4599","LU2471134523.USD","LU0471298694.HKD","LU1917777945.USD","LU0689472784.USD","LU1057294990.SGD","IE00BK4W5M84.HKD","LLY","LU1712237335.SGD","LU2468319806.SGD","NVO","BK4585","LU0466842654.USD","LU1548497426.USD","IE0009355771.USD","LU0471298777.SGD","LU1868837300.USD","LU0079474960.USD","LU1989771016.USD","LU2361045086.USD","LU0943347566.SGD","LU0114720955.EUR","LU1868837136.USD","SGXZ57979304.SGD","LU0385154629.USD","GLP","SGXZ99366536.SGD","SG9999015986.USD","SG9999013999.USD","BK4533","LU2360106947.USD","BK4007","LU0708995401.HKD","LU2361044865.SGD"],"gpt_icon":1},{"id":"2528046048","title":"两大跨国巨头称霸GLP-1市场，国产减肥药的机会在哪？","url":"https://stock-news.laohu8.com/highlight/detail?id=2528046048","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528046048?lang=zh_cn&edition=fundamental","pubTime":"2025-04-19 07:46","pubTimestamp":1745019966,"startTime":"0","endTime":"0","summary":"吃药减肥正在催生一个千亿级别的黄金赛道。高盛曾预估称，到2030年，全球抗肥胖症药物的市场规模可能会增长到约1000亿美元。在这条热门赛道，除了诺和诺德、礼来两大巨头你追我赶，另一边是包括更多中国药企也已跑步进场，展开竞速。国内已经有仁会生物的贝那鲁肽和华东医药的利拉鲁肽两款GLP-1药物正式获批减重适应证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504193381868266.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504193381868266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GLP","BK4590","BK4144"],"gpt_icon":0},{"id":"2528096721","title":"减重GLP-1制剂将进入每日一次“口服”时代 礼来回应：已在准备产能计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2528096721","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528096721?lang=zh_cn&edition=fundamental","pubTime":"2025-04-18 23:22","pubTimestamp":1744989770,"startTime":"0","endTime":"0","summary":"4月17日，礼来制药公布旗下口服GLP-1（胰高血糖素样肽-1）制剂“Orforglipron”的临床数据，在最高剂量下，每日服用一次Orforglipron的患者实现了平均减重7.3kg（7.9%）。这一表现超过了礼来之前预计的减重范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504183381594279.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504183381594279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BFTCPJ56.SGD","LU0096364046.USD","SG9999014898.SGD","LU1712237335.SGD","LU0943347566.SGD","LU2211815571.USD","LU1127390331.HKD","LU0708995401.HKD","LU2063271972.USD","LU1974910355.USD","LU2023250504.SGD","LU0238689110.USD","LLY","LU1623119135.USD","SG9999001176.USD","LU1061106388.HKD","LU0471298777.SGD","SG9999015945.SGD","LU2361044949.HKD","LU0385154629.USD","LU2265009873.SGD","LU0106261372.USD","SGXZ31699556.SGD","LU1720051017.SGD","BK4533","SGXZ51526630.SGD","LU0466842654.USD","LU1267930730.SGD","LU0882574139.USD","LU2324357040.USD","SG9999018857.SGD","LU0006306889.USD","SG9999014906.USD","LU1064131342.USD","BK4590","GLP","LU1868836914.USD","LU2089984988.USD","SGXZ81514606.USD","LU0079474960.USD","LU2491050071.SGD","LU1868836591.USD","LU2491050154.USD","SG9999014914.USD","LU1983299246.USD","LU2471134523.USD","LU1551013342.USD","LU2471134879.HKD","LU2602419157.SGD","LU0114720955.EUR"],"gpt_icon":1},{"id":"2528633910","title":"翰宇药业：全资子公司替尔泊肽原料药获韩国MFDS受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2528633910","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528633910?lang=zh_cn&edition=fundamental","pubTime":"2025-04-18 19:46","pubTimestamp":1744976778,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0077","BK0188","BK0028","BK0070","BK0239","BK4144","GLP","300199","BK4590"],"gpt_icon":0},{"id":"2528063303","title":"【翰宇药业：全资子公司替尔泊肽原料药获韩国MFDS受理】翰宇药业公告，全资子公司翰宇药业（武汉）有限公司的替尔泊肽原料药获得韩国食品药品安全厅（MFDS）的审批受理。替尔泊肽是一种新型GLP-1/GIP双受体激动剂，适用于2型糖尿病、肥胖症等治疗。该药品的受理将完善公司产品版图，提升公司竞争力，有望对公司业绩增长和行业地位产生积极影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528063303","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528063303?lang=zh_cn&edition=fundamental","pubTime":"2025-04-18 19:44","pubTimestamp":1744976653,"startTime":"0","endTime":"0","summary":"翰宇药业公告，全资子公司翰宇药业（武汉）有限公司的替尔泊肽原料药获得韩国食品药品安全厅（MFDS）的审批受理。替尔泊肽是一种新型GLP-1/GIP双受体激动剂，适用于2型糖尿病、肥胖症等治疗。该药品的受理将完善公司产品版图，提升公司竞争力，有望对公司业绩增长和行业地位产生积极影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/18194449670548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0070","BK0028","300199","BK0077","BK0188","GLP","BK4590","BK0239","BK4144"],"gpt_icon":0},{"id":"2528599300","title":"礼来预计年底前向全球监管机构提交orforglipron用于体重管理的上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2528599300","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528599300?lang=zh_cn&edition=fundamental","pubTime":"2025-04-18 17:40","pubTimestamp":1744969227,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0096364046.USD","LU0203201768.USD","GLP","LU0466842654.USD","LU1093756168.USD","LU2602419157.SGD","LU1093756325.SGD","SG9999015978.USD","LU0256863902.USD","IE00B1BXHZ80.USD","LU0006306889.USD","LU0689472784.USD","LU1720051108.HKD","LU2361044949.HKD","LU1291159041.SGD","IE00B4R5TH58.HKD","LU0058720904.USD","LU0708995401.HKD","LU1232071149.USD","LLY","LU1989771016.USD","LU0122379950.USD","LU0320765059.SGD","LU1623119135.USD","LU0238689110.USD","SG9999018857.SGD","LU0672654240.SGD","LU1720051017.SGD","LU0289739699.SGD","LU0114720955.EUR","SG9999001176.USD","LU1548497426.USD","LU0820561909.HKD","LU2264538146.SGD","BK4588","SGXZ51526630.SGD","BK4590","BK4581","LU2750360641.GBP","LU1804176565.USD","LU0094547139.USD","SG9999014898.SGD","LU0109391861.USD","BK4534","IE0009355771.USD","LU0097036916.USD","LU1057294990.SGD","SG9999001176.SGD","LU0354030511.USD","LU2471134879.HKD"],"gpt_icon":0},{"id":"2528398720","title":"GLP-1减肥药市场博弈：礼来领航突破、辉瑞折戟沉沙，创新战如何取胜？","url":"https://stock-news.laohu8.com/highlight/detail?id=2528398720","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528398720?lang=zh_cn&edition=fundamental","pubTime":"2025-04-18 15:37","pubTimestamp":1744961820,"startTime":"0","endTime":"0","summary":"全球GLP-1减肥药市场正迎来新一轮格局重塑。礼来在GLP-1赛道实现突破性进展之际，辉瑞却因安全性问题终止了口服GLP-1药物Danuglipron的研发，这也标志着其在该赛道的再次失利。在安全性方面，ACHIEVE-1研究中，orforglipron的整体安全性与GLP-1类药物一致。在礼来有效性、安全性均获得较好反响的同时，辉瑞安全性问题致口服赛道折戟。这是辉瑞在GLP-1减重药上的再次折戟。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041815395094d9c96c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041815395094d9c96c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU0122379950.USD","LU2106854487.HKD","IE00BJJMRZ35.SGD","LU0708995401.HKD","LU0820561818.USD","LLY","GLP","SG9999015945.SGD","LU2237443622.USD","BK4533","LU0234572021.USD","LU1720051108.HKD","SGXZ31699556.SGD","LU1868836914.USD","LU1974910355.USD","LU1061106388.HKD","LU2237443895.HKD","LU2357305700.SGD","LU1983299246.USD","LU0417517546.SGD","SG9999015986.USD","IE00BK4W5L77.USD","LU0203201768.USD","LU1057294990.SGD","LU2360106947.USD","LU2471134879.HKD","LU0109391861.USD","IE00B1BXHZ80.USD","LU1868836757.USD","LU1917777945.USD","BK4516","IE00BLSP4239.USD","LU2264538146.SGD","BK4599","LU1551013425.SGD","BK4581","SGXZ51526630.SGD","SGXZ99366536.SGD","LU1127390331.HKD","PFE","LU0238689110.USD","BK4007","LU0321505439.SGD","LU1988902786.USD","SG9999013999.USD","LU0943347566.SGD","SG9999017495.SGD","LU2750360641.GBP","LU1894683264.USD"],"gpt_icon":1},{"id":"2528080431","title":"礼来首个小分子口服GLP-1药物3期临床研究成功 有望颠覆减重药物格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2528080431","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528080431?lang=zh_cn&edition=fundamental","pubTime":"2025-04-18 14:07","pubTimestamp":1744956431,"startTime":"0","endTime":"0","summary":"本报讯（记者李春莲见习记者梁傲男）4月17日，全球制药巨头礼来公司公布了3期临床研究ACHIEVE-1的积极顶线结果，该研究评估了Orforglipron与安慰剂相比，在患有2型糖尿病和仅通过饮食和运动控制不足的成人中的安全性和有效性。4月17日，礼来股价收涨超14%，创下自2023年8月份以来的最大单日涨幅。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504183381169424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0289739699.SGD","LU1988902786.USD","LU2211815571.USD","LLY","IE00B2B36J28.USD","LU0094547139.USD","LU1023059063.AUD","LU0006306889.USD","LU2357305700.SGD","SG9999014880.SGD","LU1366192091.USD","LU1057294990.SGD","LU1720051108.HKD","SG9999018865.SGD","IE00BK4W5L77.USD","SG9999013999.USD","BK4533","IE00BK4W5M84.HKD","LU2237443549.SGD","IE0004445239.USD","BK4581","LU2471134523.USD","IE0009355771.USD","SG9999015945.SGD","LU0882574055.USD","LU1232071149.USD","SG9999014898.SGD","IE00BJLML261.HKD","LU0820561818.USD","LU1127390331.HKD","LU0114720955.EUR","LU1064131342.USD","SG9999017495.SGD","SGXZ31699556.SGD","GLP","LU0417517546.SGD","LU0203202063.USD","LU2237443465.HKD","LU1814569148.SGD","LU1093756168.USD","LU0079474960.USD","LU2552382132.HKD","LU0385154629.USD","LU0471298694.HKD","LU0689472784.USD","LU1983299246.USD","LU2468319806.SGD","LU2237438978.USD","LU0061475181.USD","LU1280957306.USD"],"gpt_icon":1},{"id":"2528708741","title":"美联邦法官裁定谷歌非法垄断部分广告技术市场；礼来首款GLP-1口服药报告积极三期试验结果丨全球科技早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2528708741","media":"每日经济新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528708741?lang=zh_cn&edition=fundamental","pubTime":"2025-04-18 07:59","pubTimestamp":1744934384,"startTime":"0","endTime":"0","summary":"｜2025年4月18日星期五｜NO.1美联邦法官裁定谷歌非法垄断部分广告技术市场当地时间4月17日，美国一位联邦法官表示，谷歌公司非法垄断了两个在线广告技术市场。据悉，该裁决为检察官能够主张拆分谷歌公司的广告产品提供了可能性。当天晚些时候，谷歌在一份声明中表示，将对上述裁决提起上诉，称不同意法院关于其发布商工具的裁决。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504183380604595.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504183380604595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0234570918.USD","LU0444971666.USD","LU0957791311.USD","LU0690374961.EUR","LU0114720955.EUR","LU2097344357.USD","LU0648001328.SGD","GLP","LU0238689110.USD","LU0082616367.USD","LU0314106906.USD","LU1691799644.USD","LU0128525689.USD","LLY","LU0557290698.USD","LU1699723380.USD","IE00BJTD4N35.SGD","LU0006306889.USD","LU0203202063.USD","LU0251142724.SGD","LU0690374615.EUR","LU1267930490.SGD","BK4550","SGXZ31699556.SGD","LU0122379950.USD","LU2362541513.USD","LU2404859667.USD","IE00BYQQ9H92.USD","LU0225283273.USD","LU1435385759.SGD","LU1506573853.SGD","LU2360106947.USD","USJW.SI","GOOG","LU1066051498.USD","LU1814569148.SGD","GOOGL","SG9999014898.SGD","LU0308772762.SGD","LU1244550494.USD","LU0385154629.USD","IE00BK4W5L77.USD","LU0175139822.USD","SG9999014880.SGD","LU2362541273.HKD","LU0251132253.USD","LU2242650005.HKD","LU0788109477.HKD","GB00BDT5M118.USD","LU2471134952.CNY"],"gpt_icon":1},{"id":"2528080941","title":"太平洋医药日报：礼来口服GLP-1受体激动剂ORFORGLIPRON三期临床成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2528080941","media":"太平洋证券股份...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528080941?lang=zh_cn&edition=fundamental","pubTime":"2025-04-18 00:00","pubTimestamp":1744905600,"startTime":"0","endTime":"0","summary":"行业要闻：4 月17 日，礼来宣布，公司口服GLP-1受体激动剂Orforglipron 奥格列龙在一项关键的III 期临床试验中取得了具有统计学意义的积极结果。这项研究评估了Orforglipron 与安慰剂相比，在仅通过饮食和运动控制血糖不佳的成人2 型糖尿病患者中的安全性和有效性。Orforglipron 是一种研究性的、每日一次口服的小分子（非肽）胰高血糖素样肽-1 受体激动剂，可在一天中的任何时间服用，且不受食物和饮水限制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041814031994d9b2b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"17136e9096e01d550821b3b9313a36c7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041814031994d9b2b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LLY","LU1974910355.USD","LU1023059063.AUD","LU2471134796.USD","LU1291159041.SGD","LU1093756325.SGD","LU0354030438.USD","SG9999015952.SGD","LU2063271972.USD","SGXZ57979304.SGD","LU0708995401.HKD","LU2237443382.USD","BK4581","LU1868837136.USD","LU0238689110.USD","SGXZ99366536.SGD","LU0203201768.USD","LU2211815571.USD","SG9999001176.SGD","LU0882574139.USD","BK4590","BK4007","LU2750360997.AUD","SG9999014914.USD","LU1917777945.USD","SG9999015945.SGD","LU1232071149.USD","LU1720051108.HKD","LU2360106947.USD","GLP","LU2361044949.HKD","LU0320765059.SGD","LU1989771016.USD","SG9999001176.USD","LU1868836591.USD","LU2106854487.HKD","IE00BK4W5M84.HKD","LU1868836757.USD","LU2237438978.USD","LU2468319806.SGD","LU2602419157.SGD","IE0002141913.USD","LU1057294990.SGD","LU0466842654.USD","LU2237443549.SGD","LU0256863902.USD","LU2237443465.HKD","LU2112291526.USD","BK4516","LU2491050154.USD"],"gpt_icon":1},{"id":"2528583710","title":"礼来(LLY.US)口服小分子GLP-1R激动剂III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2528583710","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528583710?lang=zh_cn&edition=fundamental","pubTime":"2025-04-17 21:12","pubTimestamp":1744895544,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月17日，礼来宣布III期ACHIEVE-1研究取得积极结果，该研究评估了orforglipron与安慰剂相比在饮食和运动单独控制不佳的2型糖尿病成人中的安全性和疗效。Orforglipron是首个成功完成III期研究的口服小分子胰高血糖素样肽-1受体激动剂，服用时无需食物和水限制。礼来表示未来该药如果获批，将对其能够在全球范围内推出orforglipron且不受供应限制充满信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1280426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0466842654.USD","LU2357305700.SGD","SG9999014898.SGD","LU0079474960.USD","LU1974910355.USD","LU1868836914.USD","IE00BK4W5L77.USD","LU0096364046.USD","SG9999014914.USD","LU2471134796.USD","LU0820561909.HKD","BK4007","LU2063271972.USD","LU2468319806.SGD","LU0203201768.USD","LU2552382058.USD","LU0256863902.USD","SGXZ99366536.SGD","IE00B2B36J28.USD","IE00BJLML261.HKD","LU1267930730.SGD","LU1868837300.USD","BK4581","SG9999015978.USD","SG9999015986.USD","SG9999015952.SGD","LU1548497426.USD","LU2112291526.USD","SG9999013999.USD","LU1989771016.USD","III","LU2361044865.SGD","LU1061106388.HKD","LU0320765059.SGD","SG9999014880.SGD","LU2324357040.USD","LU1814569148.SGD","LLY","LU2552382132.HKD","LU0097036916.USD","BK4533","SGXZ31699556.SGD","LU2471134523.USD","LU1064131342.USD","LU2750360997.AUD","GLP","LU2237443978.SGD","LU1917777945.USD","LU1868836757.USD","SG9999014906.USD"],"gpt_icon":1},{"id":"2528376858","title":"【通化东宝利拉鲁肽注射液获哥伦比亚GMP证书】 近日，通化东宝与合作伙伴科兴生物制药股份有限公司携手的出海产品—利拉鲁肽注射液，正式获得哥伦比亚国家食品药品监督管理局颁发的GMP证书，为后续该产品在哥伦比亚的获批上市，以及拉美其他国家的市场准入打下坚实基础。利拉鲁肽注射液作为GLP-1受体激动剂，凭借其降糖、减重及心血管保护的多重疗效，已成为全球糖尿病治疗的一线药物，受到患者的广泛认可。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528376858","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528376858?lang=zh_cn&edition=fundamental","pubTime":"2025-04-17 15:41","pubTimestamp":1744875705,"startTime":"0","endTime":"0","summary":"近日，通化东宝与合作伙伴科兴生物制药股份有限公司携手的出海产品—利拉鲁肽注射液，正式获得哥伦比亚国家食品药品监督管理局颁发的GMP证书，为后续该产品在哥伦比亚的获批上市，以及拉美其他国家的市场准入打下坚实基础。利拉鲁肽注射液作为GLP-1受体激动剂，凭借其降糖、减重及心血管保护的多重疗效，已成为全球糖尿病治疗的一线药物，受到患者的广泛认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/17154149616448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","BK0188","BK4144","600867","01477","BK1574","BK0196","SVA","BK0239","GLP","BK1191","BK4590"],"gpt_icon":0},{"id":"2527716404","title":"下一代减肥药：跨越GLP-1巅峰","url":"https://stock-news.laohu8.com/highlight/detail?id=2527716404","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527716404?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 09:41","pubTimestamp":1744767666,"startTime":"0","endTime":"0","summary":"下一代减肥药的研发图谱，已然展开。相较于已诞生替尔泊肽这一明星药物的GLP-1/GIP组合，GLP-1与amylin的联用是更为新颖的尝试。罗氏明确表示，petrelintide具备单药治疗以及与GLP-1/GIP受体双重激动剂CT-388形成固定剂量组合的潜力。这并非礼来首次涉足三靶点减肥药研发。临床前数据显示，LX9851单药治疗可显著降低肥胖小鼠的体重、食物摄入量和脂肪量，与司美格鲁肽联合使用时，减重效果进一步增强，并有效减轻了GLP-1药物治疗后的体重反弹现象。","market":"us","thumbnail":"http://imgcloud.jrjimg.cn/2025/04/cms_20250416094106543.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2025/04/cms_20250416094106543.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://ky.jrj.com.cn/2025/04/16094149570264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["GLP","BK4590","BK4144"],"gpt_icon":0},{"id":"2527490432","title":"辉瑞再终止GLP-1药物开发！罗氏、艾伯维等弯道超车？","url":"https://stock-news.laohu8.com/highlight/detail?id=2527490432","media":"医药经济报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527490432?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 19:34","pubTimestamp":1744716855,"startTime":"0","endTime":"0","summary":"4月14日，辉瑞宣布终止开发口服GLP-1激动剂Danuglipron，该药物此前正在研究用于慢性体重管理。这是辉瑞在GLP-1减重药上的再次折戟。在审查了全部信息后，包括迄今为止Danuglipron的所有临床数据以及监管机构的最新意见，辉瑞决定终止开发该分子。不可否认的是，摆在GLP-1赛道选手眼前的一大难关是肝损伤、胃肠道反应高等安全性问题。Petrelintide 耐受性良好，未发生严重或严重不良事件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415194538a459a501&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415194538a459a501&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1061106388.HKD","LU0949170772.SGD","LU0965508806.USD","LU2237443622.USD","LU0943347566.SGD","IE00BGHQF631.EUR","LU0211328371.USD","LU0912757837.SGD","LU1839511570.USD","LU1244550577.SGD","LU2089284900.SGD","PFE","LU1244550221.USD","SG9999002232.USD","BK4139","LU2023251221.USD","IE0002141913.USD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","GLP","LU0058720904.USD","LU0225284248.USD","LU0321505868.SGD","LU0545039389.USD","SG9999011175.SGD","LU2237443978.SGD","IE0002270589.USD","LU0820561909.HKD","LU1585245621.USD","LU1989772923.USD","LU1983299246.USD","IE00BDGV0183.EUR","BK4007","IE00BJT1NW94.SGD","LU1093756325.SGD","LU1989771016.USD","LU0708994859.HKD","LU0203347892.USD","BK4559","LU1066053197.SGD","LU2237443382.USD","LU0234570918.USD","LU0689472784.USD","LU0795875169.SGD","ABBV","IE00B4R5TH58.HKD","LU0321505439.SGD","SG9999002224.SGD","LU0029864427.USD","BK4550"],"gpt_icon":1},{"id":"2527499611","title":"1名受试者出现肝损伤，辉瑞终止一款口服减肥药临床开发，死磕小分子GLP-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499611","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499611?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 18:55","pubTimestamp":1744714542,"startTime":"0","endTime":"0","summary":"一款口服减重药折戟。图片来源：图虫创意跨国药企辉瑞又终止一款口服GLP-1R激动剂的临床开发。时代财经从辉瑞获悉，美国时间4月14日，辉瑞宣布决定终止开发每日一次的口服GLP-1R激动剂Danuglipron，该药物用于减重管理。由于安全性问题待解，辉瑞经多方考虑后选择终止开发这一小分子药物。而在Danuglipron之前，早在2023年6月，辉瑞就终止了其旗下另一款GLP-1R小分子激动剂项目Lotiglipron的后续研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415185615973879d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415185615973879d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456855351.SGD","LU0306807586.USD","LU1066051498.USD","LU0985481810.HKD","SG9999011175.SGD","BK4144","IE00BLSP4452.SGD","BK4585","BK4599","LU1894683264.USD","LU1057294990.SGD","SG9999001176.USD","BK4590","SGXZ57979304.SGD","GLP","IE00BBT3K403.USD","LU1894683348.USD","BK4581","BK4533","BK4534","BK4588","LU0306806265.USD","IE00B19Z3B42.SGD","LU1883839398.USD","SG9999001176.SGD","BK4007","LU0225284248.USD","LU0868494617.USD","IE00B19Z3581.USD","SG9999013999.USD","IE000M9KFDE8.USD","BK4550","IE00BLSP4239.USD","IE0002270589.USD","LU0225771236.USD","LU1066053197.SGD","LU0321505439.SGD","LU0234572021.USD","SG9999002224.SGD","LU0170899867.USD","LU0289739699.SGD","BK4568","SG9999003800.SGD","LU1023059063.AUD","LU0122379950.USD","PFE","BK4592","SG9999002232.USD","LU0321505868.SGD","LU0058720904.USD"],"gpt_icon":1},{"id":"2527341315","title":"辉瑞又双叒叕放弃一款口服 GLP-1，肥胖管线仅剩 1 款药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2527341315","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527341315?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 11:45","pubTimestamp":1744688751,"startTime":"0","endTime":"0","summary":"当地时间 4 月 14 日，辉瑞宣布终止开发口服胰高血糖素样肽-1受体激动剂 Danuglipron。安慰剂校正后，32 周时平均体重下降 8% 至 13%，26 周时平均体重下降 5% 至 9.5%。然而此次出现的潜在肝损伤病例，每日一次的Danuglipron 也终被辉瑞放弃。Danuglipron 并不是辉瑞在肥胖领域首次折戟的药物。在先后终止 Lotiglipron 和Danuglipron 开发后，目前辉瑞的肥胖药物管线仅剩一款口服 GIPR 拮抗剂PF-07976016，全球最高状态处于临床 II 期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415200413a459a994&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415200413a459a994&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU0456855351.SGD","LU0985481810.HKD","BK4007","SG9999013999.USD","IE00BLSP4239.USD","BK4581","LU0234572021.USD","LU1894683348.USD","BK4592","SG9999011175.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0306806265.USD","BK4534","LU1894683264.USD","LU0170899867.USD","IE00B19Z3581.USD","BK4590","LU0225284248.USD","LU0321505439.SGD","SG9999002224.SGD","LU0321505868.SGD","LU1066051498.USD","LU1023059063.AUD","BK4533","SG9999001176.USD","IE00B19Z3B42.SGD","SG9999003800.SGD","LU0289739699.SGD","LU0868494617.USD","PFE","LU0058720904.USD","IE0002270589.USD","LU0306807586.USD","BK4588","BK4144","LU0225771236.USD","BK4568","IE000M9KFDE8.USD","SG9999001176.SGD","BK4550","BK4599","LU1066053197.SGD","SG9999002232.USD","LU0122379950.USD","LU1883839398.USD","GLP","LU1057294990.SGD","IE00BLSP4452.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":147,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GLP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-28","symbol":"GLP","fiscalQuarterEnding":"2024/12","expectedEps":0.24,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740718800000,"reportTimeType":"pre","actualEps":0.52},{"date":"2025-02-10","symbol":"GLP","amount":0.74,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-10","defaultRemindTime":1739197800000,"name":"全球合伙","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-14","payableDate":"2025-02-10","currency":"USD","dateTimestamp":1739163600000,"payDate":"2025-02-14"},{"date":"2024-11-08","symbol":"GLP","amount":0.73,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-08","defaultRemindTime":1731076200000,"name":"全球合伙","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-14","payableDate":"2024-11-08","currency":"USD","dateTimestamp":1731042000000,"payDate":"2024-11-14"},{"market":"US","date":"2024-11-08","symbol":"GLP","fiscalQuarterEnding":"2024/09","expectedEps":1.57,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731042000000,"reportTimeType":"pre","actualEps":1.17},{"date":"2024-08-08","symbol":"GLP","amount":0.72,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-08-08","defaultRemindTime":1723123800000,"name":"全球合伙","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-08-14","payableDate":"2024-08-08","currency":"USD","dateTimestamp":1723089600000,"payDate":"2024-08-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GLP\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-04","recordDate":"2015-05-06","paymentDate":"2015-05-15","value":0.68,"currency":"USD"},{"executeDate":"2015-08-03","recordDate":"2015-08-05","paymentDate":"2015-08-14","value":0.6925,"currency":"USD"},{"executeDate":"2015-11-02","recordDate":"2015-11-04","paymentDate":"2015-11-13","value":0.6975,"currency":"USD"},{"executeDate":"2016-02-08","recordDate":"2016-02-10","paymentDate":"2016-02-16","value":0.4625,"currency":"USD"},{"executeDate":"2016-05-04","recordDate":"2016-05-06","paymentDate":"2016-05-16","value":0.4625,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GLP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":2,"updateTime":1741233600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GLP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GLP","date":"2025-04-21","current":18.509538,"percent":0.885273,"low":2.771386,"twenty":4.270877,"median":9.726256,"eighty":15.350956,"high":29.34912,"avg":10.428443,"sd":6.24379,"marketCap":1709337357},"quantilePoints":[{"date":"2020-04-24","current":10.885399,"twenty":6.299451,"median":7.87934,"eighty":11.115597,"marketCap":375415632},{"date":"2020-05-01","current":11.300646,"twenty":6.299659,"median":7.88907,"eighty":11.255307,"marketCap":389736665},{"date":"2020-05-08","current":11.690231,"twenty":6.299659,"median":7.896854,"eighty":11.255307,"marketCap":361461939},{"date":"2020-05-15","current":10.863092,"twenty":6.299659,"median":7.912422,"eighty":11.245121,"marketCap":335886802},{"date":"2020-05-22","current":11.182919,"twenty":6.299659,"median":7.932539,"eighty":11.262234,"marketCap":345775855},{"date":"2020-05-29","current":11.24909,"twenty":6.299659,"median":7.943558,"eighty":11.269162,"marketCap":347821866},{"date":"2020-06-05","current":12.451199,"twenty":6.307959,"median":7.955234,"eighty":11.298028,"marketCap":384991066},{"date":"2020-06-12","current":11.557889,"twenty":6.309309,"median":7.998046,"eighty":11.32112,"marketCap":357369917},{"date":"2020-06-19","current":11.072634,"twenty":6.3117,"median":8.066523,"eighty":11.332667,"marketCap":342365837},{"date":"2020-06-26","current":10.708693,"twenty":6.3117,"median":8.171888,"eighty":11.326893,"marketCap":331112776},{"date":"2020-07-02","current":10.752807,"twenty":6.317715,"median":8.211094,"eighty":11.322275,"marketCap":332476784},{"date":"2020-07-10","current":10.43298,"twenty":6.321861,"median":8.267451,"eighty":11.32112,"marketCap":322587731},{"date":"2020-07-17","current":10.13521,"twenty":6.32825,"median":8.287054,"eighty":11.316433,"marketCap":313380681},{"date":"2020-07-24","current":10.543265,"twenty":6.333279,"median":8.291955,"eighty":11.303569,"marketCap":325997749},{"date":"2020-07-31","current":11.800516,"twenty":6.334178,"median":8.348313,"eighty":11.303569,"marketCap":364871958},{"date":"2020-08-07","current":4.73435,"twenty":6.333279,"median":8.360564,"eighty":11.32112,"marketCap":438154667},{"date":"2020-08-14","current":5.006778,"twenty":6.3117,"median":8.298445,"eighty":11.316433,"marketCap":463367300},{"date":"2020-08-21","current":4.712262,"twenty":6.299659,"median":8.287054,"eighty":11.303569,"marketCap":436110400},{"date":"2020-08-28","current":4.701217,"twenty":6.299607,"median":8.274802,"eighty":11.298552,"marketCap":435088266},{"date":"2020-09-04","current":4.542915,"twenty":6.2824,"median":8.213544,"eighty":11.285346,"marketCap":420437682},{"date":"2020-09-11","current":4.749076,"twenty":6.27606,"median":8.174338,"eighty":11.274368,"marketCap":439517512},{"date":"2020-09-18","current":4.815342,"twenty":6.275736,"median":8.086126,"eighty":11.269162,"marketCap":445650315},{"date":"2020-09-25","current":4.73435,"twenty":6.258044,"median":8.00583,"eighty":11.265698,"marketCap":438154667},{"date":"2020-10-02","current":4.933149,"twenty":6.250305,"median":7.971673,"eighty":11.259925,"marketCap":456553075},{"date":"2020-10-09","current":5.360198,"twenty":6.244429,"median":7.94745,"eighty":11.2525,"marketCap":496075580},{"date":"2020-10-16","current":5.26448,"twenty":6.239772,"median":7.932539,"eighty":11.247278,"marketCap":487217087},{"date":"2020-10-23","current":5.271843,"twenty":6.23717,"median":7.912422,"eighty":11.243223,"marketCap":487898510},{"date":"2020-10-30","current":5.338109,"twenty":6.227089,"median":7.896854,"eighty":11.239367,"marketCap":494031312},{"date":"2020-11-06","current":5.459545,"twenty":6.22179,"median":7.88907,"eighty":11.21862,"marketCap":522855188},{"date":"2020-11-13","current":5.670214,"twenty":6.203808,"median":7.87934,"eighty":11.19873,"marketCap":543030764},{"date":"2020-11-20","current":5.877313,"twenty":6.196135,"median":7.85015,"eighty":11.194013,"marketCap":562864382},{"date":"2020-11-27","current":6.170107,"twenty":6.185826,"median":7.85015,"eighty":11.189536,"marketCap":590905013},{"date":"2020-12-04","current":6.109406,"twenty":6.168749,"median":7.838474,"eighty":11.169685,"marketCap":585091712},{"date":"2020-12-11","current":6.416483,"twenty":6.167844,"median":7.834582,"eighty":11.145422,"marketCap":614500179},{"date":"2020-12-18","current":6.230809,"twenty":6.167844,"median":7.828744,"eighty":11.130907,"marketCap":596718315},{"date":"2020-12-24","current":6.048705,"twenty":6.167844,"median":7.82096,"eighty":11.115597,"marketCap":579278410},{"date":"2020-12-31","current":5.934444,"twenty":6.167844,"median":7.817068,"eighty":11.101741,"marketCap":568335725},{"date":"2021-01-08","current":6.062987,"twenty":6.149862,"median":7.795662,"eighty":11.084422,"marketCap":580646246},{"date":"2021-01-15","current":6.216526,"twenty":6.149862,"median":7.785585,"eighty":11.084422,"marketCap":595350479},{"date":"2021-01-22","current":6.705707,"twenty":6.149862,"median":7.780094,"eighty":11.074992,"marketCap":642198851},{"date":"2021-01-29","current":7.180605,"twenty":6.149862,"median":7.776202,"eighty":11.068208,"marketCap":687679388},{"date":"2021-02-05","current":7.284155,"twenty":6.149862,"median":7.768418,"eighty":11.06411,"marketCap":697596196},{"date":"2021-02-12","current":6.934229,"twenty":6.163202,"median":7.760634,"eighty":11.053134,"marketCap":664084222},{"date":"2021-02-19","current":7.112763,"twenty":6.167321,"median":7.75285,"eighty":11.04396,"marketCap":681182168},{"date":"2021-02-26","current":7.202029,"twenty":6.167844,"median":7.741174,"eighty":11.038761,"marketCap":689731141},{"date":"2021-03-05","current":6.896217,"twenty":6.167844,"median":7.718575,"eighty":11.032407,"marketCap":695214499},{"date":"2021-03-12","current":7.842623,"twenty":6.167844,"median":7.698362,"eighty":11.017031,"marketCap":790622686},{"date":"2021-03-19","current":7.720506,"twenty":6.167844,"median":7.718575,"eighty":11.007626,"marketCap":778311953},{"date":"2021-03-26","current":7.411822,"twenty":6.167844,"median":7.69367,"eighty":11.00501,"marketCap":747193153},{"date":"2021-04-01","current":7.320234,"twenty":6.167844,"median":7.686686,"eighty":10.988222,"marketCap":737960103},{"date":"2021-04-09","current":7.3779,"twenty":6.167844,"median":7.67501,"eighty":10.954813,"marketCap":743773505},{"date":"2021-04-16","current":7.510194,"twenty":6.168749,"median":7.659442,"eighty":10.940212,"marketCap":757110133},{"date":"2021-04-23","current":7.364332,"twenty":6.170107,"median":7.594997,"eighty":10.930856,"marketCap":742405645},{"date":"2021-04-30","current":8.185229,"twenty":6.171613,"median":7.641929,"eighty":10.912383,"marketCap":825161134},{"date":"2021-05-07","current":9.181725,"twenty":6.178654,"median":7.67501,"eighty":10.905455,"marketCap":849502414},{"date":"2021-05-14","current":8.749253,"twenty":6.185826,"median":7.686686,"eighty":10.905455,"marketCap":809489619},{"date":"2021-05-21","current":9.203903,"twenty":6.185826,"median":7.690578,"eighty":10.897433,"marketCap":851554353},{"date":"2021-05-28","current":9.407203,"twenty":6.185826,"median":7.712361,"eighty":10.877257,"marketCap":870363786},{"date":"2021-06-04","current":9.706607,"twenty":6.189262,"median":7.720506,"eighty":10.864653,"marketCap":898064952},{"date":"2021-06-11","current":10.061456,"twenty":6.203126,"median":7.741174,"eighty":10.858681,"marketCap":930895963},{"date":"2021-06-18","current":9.603109,"twenty":6.203644,"median":7.748958,"eighty":10.836624,"marketCap":888489240},{"date":"2021-06-25","current":9.680732,"twenty":6.203808,"median":7.760634,"eighty":10.817799,"marketCap":895671024},{"date":"2021-07-02","current":9.658554,"twenty":6.203808,"median":7.768418,"eighty":10.809851,"marketCap":893619086},{"date":"2021-07-09","current":9.31849,"twenty":6.203808,"median":7.778148,"eighty":10.796921,"marketCap":862156033},{"date":"2021-07-16","current":8.963641,"twenty":6.213362,"median":7.780094,"eighty":10.785892,"marketCap":829325022},{"date":"2021-07-23","current":9.495915,"twenty":6.213362,"median":7.785616,"eighty":10.763835,"marketCap":878571539},{"date":"2021-07-30","current":9.909906,"twenty":6.216526,"median":7.795662,"eighty":10.752807,"marketCap":916874385},{"date":"2021-08-06","current":29.34912,"twenty":6.22179,"median":7.817068,"eighty":10.752807,"marketCap":823536295},{"date":"2021-08-13","current":26.023372,"twenty":6.22179,"median":7.822906,"eighty":10.813084,"marketCap":730215805},{"date":"2021-08-20","current":24.554702,"twenty":6.22179,"median":7.83069,"eighty":10.865043,"marketCap":689004931},{"date":"2021-08-27","current":24.530426,"twenty":6.22179,"median":7.834582,"eighty":10.905455,"marketCap":688323760},{"date":"2021-09-03","current":25.100901,"twenty":6.22179,"median":7.842494,"eighty":10.964493,"marketCap":704331289},{"date":"2021-09-10","current":24.275533,"twenty":6.228856,"median":7.848204,"eighty":11.013201,"marketCap":681171460},{"date":"2021-09-17","current":25.198003,"twenty":6.230622,"median":7.85015,"eighty":11.053134,"marketCap":707055975},{"date":"2021-09-24","current":24.894559,"twenty":6.230772,"median":7.876969,"eighty":11.084422,"marketCap":698541332},{"date":"2021-10-01","current":26.047647,"twenty":6.233421,"median":7.883329,"eighty":11.141011,"marketCap":730896976},{"date":"2021-10-08","current":26.897291,"twenty":6.234318,"median":7.892962,"eighty":11.19642,"marketCap":754737977},{"date":"2021-10-15","current":26.836602,"twenty":6.236185,"median":7.896854,"eighty":11.246674,"marketCap":753035049},{"date":"2021-10-22","current":28.632991,"twenty":6.237348,"median":7.914368,"eighty":11.269162,"marketCap":803441737},{"date":"2021-10-29","current":28.329547,"twenty":6.237865,"median":7.935774,"eighty":11.303569,"marketCap":794927093},{"date":"2021-11-05","current":18.151279,"twenty":6.239408,"median":7.94745,"eighty":11.328048,"marketCap":776838422},{"date":"2021-11-12","current":18.191189,"twenty":6.239772,"median":7.988112,"eighty":11.346522,"marketCap":778546510},{"date":"2021-11-19","current":18.773882,"twenty":6.239772,"median":8.014118,"eighty":11.360961,"marketCap":803484595},{"date":"2021-11-26","current":18.694061,"twenty":6.239772,"median":8.035981,"eighty":11.378852,"marketCap":800068419},{"date":"2021-12-03","current":18.103386,"twenty":6.239772,"median":8.105729,"eighty":11.403489,"marketCap":774788716},{"date":"2021-12-10","current":18.430652,"twenty":6.240495,"median":8.179783,"eighty":11.427136,"marketCap":788795038},{"date":"2021-12-17","current":18.550383,"twenty":6.243048,"median":8.213544,"eighty":11.470285,"marketCap":793919302},{"date":"2021-12-23","current":17.991637,"twenty":6.244429,"median":8.252749,"eighty":11.474686,"marketCap":770006070},{"date":"2021-12-31","current":18.749936,"twenty":6.244429,"median":8.284603,"eighty":11.575574,"marketCap":802459742},{"date":"2022-01-07","current":20.051017,"twenty":6.24581,"median":8.291955,"eighty":11.616705,"marketCap":858143411},{"date":"2022-01-14","current":21.152545,"twenty":6.248234,"median":8.320498,"eighty":11.690231,"marketCap":905286640},{"date":"2022-01-21","current":20.146802,"twenty":6.249277,"median":8.363015,"eighty":11.729858,"marketCap":862242822},{"date":"2022-01-28","current":21.392008,"twenty":6.251718,"median":8.365465,"eighty":11.776801,"marketCap":915535168},{"date":"2022-02-04","current":21.85497,"twenty":6.254157,"median":8.433466,"eighty":11.837284,"marketCap":935348988},{"date":"2022-02-11","current":21.559632,"twenty":6.257754,"median":8.47328,"eighty":11.938846,"marketCap":922709137},{"date":"2022-02-18","current":20.945011,"twenty":6.257851,"median":8.48054,"eighty":12.432666,"marketCap":896404582},{"date":"2022-02-25","current":20.529942,"twenty":6.258237,"median":8.487891,"eighty":12.775373,"marketCap":878640467},{"date":"2022-03-04","current":15.348683,"twenty":6.268592,"median":8.571294,"eighty":13.121553,"marketCap":878174885},{"date":"2022-03-11","current":15.504022,"twenty":6.275496,"median":8.601399,"eighty":13.154839,"marketCap":887062603},{"date":"2022-03-18","current":15.940166,"twenty":6.275736,"median":8.649704,"eighty":13.201441,"marketCap":912016580},{"date":"2022-03-25","current":16.890123,"twenty":6.275736,"median":8.669307,"eighty":13.248042,"marketCap":966368393},{"date":"2022-04-01","current":16.214996,"twenty":6.275736,"median":8.68891,"eighty":13.261356,"marketCap":927741004},{"date":"2022-04-08","current":16.752708,"twenty":6.275736,"median":8.726599,"eighty":13.281328,"marketCap":958506181},{"date":"2022-04-14","current":16.573471,"twenty":6.275736,"median":8.736337,"eighty":13.3013,"marketCap":948251122},{"date":"2022-04-22","current":16.011861,"twenty":6.276168,"median":8.777122,"eighty":13.329261,"marketCap":916118604},{"date":"2022-04-29","current":15.743005,"twenty":6.281175,"median":8.797306,"eighty":13.342575,"marketCap":900736015},{"date":"2022-05-06","current":9.804164,"twenty":6.2824,"median":8.848712,"eighty":13.349233,"marketCap":897659497},{"date":"2022-05-13","current":9.69216,"twenty":6.2824,"median":8.9103,"eighty":13.347901,"marketCap":887404438},{"date":"2022-05-20","current":10.270852,"twenty":6.291454,"median":8.930374,"eighty":13.347901,"marketCap":940388910},{"date":"2022-05-27","current":11.163158,"twenty":6.293718,"median":8.972794,"eighty":13.342575,"marketCap":1022087547},{"date":"2022-06-03","current":10.868211,"twenty":6.294536,"median":8.995202,"eighty":13.341244,"marketCap":995082558},{"date":"2022-06-10","current":10.244717,"twenty":6.297672,"median":9.026396,"eighty":13.341244,"marketCap":937996063},{"date":"2022-06-17","current":7.754474,"twenty":6.299555,"median":9.016925,"eighty":13.33725,"marketCap":709991918},{"date":"2022-06-24","current":8.613179,"twenty":6.299659,"median":8.99034,"eighty":13.331924,"marketCap":788614037},{"date":"2022-07-01","current":8.814788,"twenty":6.299659,"median":8.977241,"eighty":13.322603,"marketCap":807073143},{"date":"2022-07-08","current":8.900658,"twenty":6.299659,"median":8.963641,"eighty":13.313284,"marketCap":814935355},{"date":"2022-07-15","current":8.867057,"twenty":6.299659,"median":8.92485,"eighty":13.306626,"marketCap":811858837},{"date":"2022-07-22","current":9.561487,"twenty":6.300172,"median":8.963641,"eighty":13.3013,"marketCap":875440203},{"date":"2022-07-29","current":10.371656,"twenty":6.303369,"median":8.980096,"eighty":13.299969,"marketCap":949618463},{"date":"2022-08-05","current":3.850073,"twenty":6.303369,"median":8.997729,"eighty":13.29198,"marketCap":927520968},{"date":"2022-08-12","current":4.016293,"twenty":6.299659,"median":8.972794,"eighty":13.281328,"marketCap":967565231},{"date":"2022-08-19","current":3.999245,"twenty":6.293991,"median":8.937993,"eighty":13.278687,"marketCap":963458127},{"date":"2022-08-26","current":3.899797,"twenty":6.2824,"median":8.919306,"eighty":13.268103,"marketCap":939500021},{"date":"2022-09-02","current":4.077383,"twenty":6.275736,"median":8.9103,"eighty":13.268014,"marketCap":982282354},{"date":"2022-09-09","current":4.169728,"twenty":6.275496,"median":8.900658,"eighty":13.268014,"marketCap":1004529167},{"date":"2022-09-16","current":4.014873,"twenty":6.257754,"median":8.857885,"eighty":13.261356,"marketCap":967222973},{"date":"2022-09-23","current":3.607134,"twenty":6.247881,"median":8.814788,"eighty":13.254699,"marketCap":868994737},{"date":"2022-09-30","current":3.51621,"twenty":6.240977,"median":8.791187,"eighty":13.254699,"marketCap":847090183},{"date":"2022-10-07","current":3.916845,"twenty":6.239772,"median":8.777122,"eighty":13.248042,"marketCap":943607125},{"date":"2022-10-14","current":3.740679,"twenty":6.236636,"median":8.755886,"eighty":13.248042,"marketCap":901167051},{"date":"2022-10-21","current":4.087328,"twenty":6.230622,"median":8.734756,"eighty":13.241384,"marketCap":984678164},{"date":"2022-10-28","current":4.250707,"twenty":6.22179,"median":8.716798,"eighty":13.234727,"marketCap":1024037910},{"date":"2022-11-04","current":3.449288,"twenty":6.213362,"median":8.68891,"eighty":13.208098,"marketCap":1095762902},{"date":"2022-11-11","current":3.301892,"twenty":6.203808,"median":8.669307,"eighty":13.201441,"marketCap":1048938349},{"date":"2022-11-18","current":3.311575,"twenty":6.185826,"median":8.649704,"eighty":13.194783,"marketCap":1052014414},{"date":"2022-11-25","current":3.399797,"twenty":6.17312,"median":8.639313,"eighty":13.17348,"marketCap":1080040789},{"date":"2022-12-02","current":3.385811,"twenty":6.167844,"median":8.62969,"eighty":13.162828,"marketCap":1075597583},{"date":"2022-12-09","current":3.518145,"twenty":6.167844,"median":8.601399,"eighty":13.156171,"marketCap":1117637146},{"date":"2022-12-16","current":3.574091,"twenty":6.149862,"median":8.577106,"eighty":13.154839,"marketCap":1135409969},{"date":"2022-12-23","current":3.865656,"twenty":6.146266,"median":8.549709,"eighty":13.144188,"marketCap":1228033720},{"date":"2022-12-30","current":3.740853,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1188386653},{"date":"2023-01-06","current":3.441757,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1093370406},{"date":"2023-01-13","current":3.612823,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1147714231},{"date":"2023-01-20","current":3.620354,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1150106726},{"date":"2023-01-27","current":3.857048,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1225299440},{"date":"2023-02-03","current":4.130323,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1312112845},{"date":"2023-02-10","current":3.93774,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1250933319},{"date":"2023-02-17","current":3.875339,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1231109786},{"date":"2023-02-24","current":3.718259,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1181209167},{"date":"2023-03-03","current":3.363192,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1194165378},{"date":"2023-03-10","current":3.211151,"twenty":6.113691,"median":8.482899,"eighty":13.133536,"marketCap":1140180220},{"date":"2023-03-17","current":2.830086,"twenty":6.097582,"median":8.463126,"eighty":13.133536,"marketCap":1004875645},{"date":"2023-03-24","current":2.875313,"twenty":6.070129,"median":8.365465,"eighty":13.133536,"marketCap":1020934521},{"date":"2023-03-31","current":2.985014,"twenty":6.034422,"median":8.291955,"eighty":13.130873,"marketCap":1059885838},{"date":"2023-04-06","current":2.892634,"twenty":6.016569,"median":8.274802,"eighty":13.130873,"marketCap":1027084729},{"date":"2023-04-14","current":2.896483,"twenty":5.960153,"median":8.185229,"eighty":13.133536,"marketCap":1028451442},{"date":"2023-04-20","current":2.925352,"twenty":5.879004,"median":8.105729,"eighty":13.133536,"marketCap":1038701788},{"date":"2023-04-28","current":2.932088,"twenty":5.726233,"median":7.998046,"eighty":13.136199,"marketCap":1041093536},{"date":"2023-05-05","current":2.771386,"twenty":5.536171,"median":7.943558,"eighty":13.136199,"marketCap":984033273},{"date":"2023-05-12","current":2.975648,"twenty":5.442294,"median":7.932539,"eighty":13.136199,"marketCap":1050433502},{"date":"2023-05-19","current":3.089052,"twenty":5.341054,"median":7.932539,"eighty":13.136199,"marketCap":1090466310},{"date":"2023-05-26","current":2.874844,"twenty":5.253436,"median":7.932539,"eighty":13.136199,"marketCap":1014848784},{"date":"2023-06-02","current":2.846736,"twenty":5.130475,"median":7.932539,"eighty":13.136199,"marketCap":1004926122},{"date":"2023-06-09","current":3.07839,"twenty":5.004569,"median":7.932539,"eighty":13.136199,"marketCap":1086702542},{"date":"2023-06-16","current":3.058036,"twenty":4.918423,"median":7.932539,"eighty":13.136199,"marketCap":1079517166},{"date":"2023-06-23","current":2.916523,"twenty":4.864674,"median":7.935774,"eighty":13.138862,"marketCap":1029561696},{"date":"2023-06-30","current":2.952386,"twenty":4.815342,"median":7.93772,"eighty":13.141525,"marketCap":1042221644},{"date":"2023-07-07","current":2.944631,"twenty":4.771165,"median":7.93772,"eighty":13.141525,"marketCap":1039484358},{"date":"2023-07-14","current":3.066759,"twenty":4.749076,"median":7.93772,"eighty":13.141525,"marketCap":1082596613},{"date":"2023-07-21","current":3.116192,"twenty":4.697536,"median":7.93772,"eighty":13.141525,"marketCap":1100046811},{"date":"2023-07-28","current":3.215057,"twenty":4.671766,"median":7.93772,"eighty":13.141525,"marketCap":1134947207},{"date":"2023-08-04","current":3.279998,"twenty":4.616544,"median":7.93772,"eighty":13.141525,"marketCap":1157871978},{"date":"2023-08-11","current":4.645552,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075069076},{"date":"2023-08-18","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-08-25","current":4.663295,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1079175005},{"date":"2023-09-01","current":4.624853,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1070278826},{"date":"2023-09-08","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-09-15","current":4.775663,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1105179222},{"date":"2023-09-22","current":4.867332,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1126393189},{"date":"2023-09-29","current":5.173389,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1197220464},{"date":"2023-10-06","current":4.475521,"twenty":4.542915,"median":7.93772,"eighty":13.141525,"marketCap":1035720590},{"date":"2023-10-13","current":4.511006,"twenty":4.484012,"median":7.93772,"eighty":13.141525,"marketCap":1043932448},{"date":"2023-10-20","current":4.482914,"twenty":4.482914,"median":7.93772,"eighty":13.141525,"marketCap":1037431394},{"date":"2023-10-27","current":4.534662,"twenty":4.467537,"median":7.94745,"eighty":13.149513,"marketCap":1049407020},{"date":"2023-11-03","current":4.904296,"twenty":4.458666,"median":7.94745,"eighty":13.149513,"marketCap":1134947207},{"date":"2023-11-10","current":7.439549,"twenty":4.458666,"median":7.935774,"eighty":13.149513,"marketCap":1088071185},{"date":"2023-11-17","current":7.820894,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1143844827},{"date":"2023-11-24","current":7.993518,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1169092039},{"date":"2023-12-01","current":8.460278,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1237357955},{"date":"2023-12-08","current":8.743603,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1278795691},{"date":"2023-12-15","current":8.690189,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1270983658},{"date":"2023-12-22","current":9.616802,"twenty":4.459848,"median":7.934448,"eighty":13.146851,"marketCap":1406505433},{"date":"2023-12-29","current":9.686473,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1416695040},{"date":"2024-01-05","current":9.75382,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1426544994},{"date":"2024-01-12","current":9.809556,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1434696679},{"date":"2024-01-19","current":10.16023,"twenty":4.448612,"median":7.939666,"eighty":13.154839,"marketCap":1485984368},{"date":"2024-01-26","current":10.740814,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1570897761},{"date":"2024-02-02","current":10.601474,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1550518547},{"date":"2024-02-09","current":10.963759,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1603504503},{"date":"2024-02-16","current":11.124,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1626940600},{"date":"2024-02-23","current":10.647921,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1557311618},{"date":"2024-03-01","current":11.10678,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1583804596},{"date":"2024-03-08","current":11.32675,"twenty":4.4563,"median":7.94745,"eighty":13.154839,"marketCap":1615171958},{"date":"2024-03-15","current":10.799262,"twenty":4.4563,"median":7.990262,"eighty":13.154839,"marketCap":1539953125},{"date":"2024-03-22","current":11.659401,"twenty":4.4563,"median":8.049544,"eighty":13.154839,"marketCap":1662607257},{"date":"2024-03-28","current":10.571159,"twenty":4.4563,"median":8.239503,"eighty":13.154839,"marketCap":1507426062},{"date":"2024-04-05","current":10.811142,"twenty":4.452456,"median":8.461702,"eighty":13.154839,"marketCap":1541647243},{"date":"2024-04-12","current":11.186562,"twenty":4.452456,"median":8.566313,"eighty":13.154839,"marketCap":1595181367},{"date":"2024-04-19","current":10.81827,"twenty":4.452456,"median":8.624771,"eighty":13.154839,"marketCap":1542663714},{"date":"2024-04-26","current":11.245964,"twenty":4.4563,"median":8.639313,"eighty":13.154839,"marketCap":1603651956},{"date":"2024-05-03","current":11.324374,"twenty":4.4563,"median":8.690189,"eighty":13.154839,"marketCap":1614833134},{"date":"2024-05-10","current":14.682959,"twenty":4.4563,"median":8.734756,"eighty":13.168154,"marketCap":1565364893},{"date":"2024-05-17","current":13.78037,"twenty":4.4563,"median":8.734756,"eighty":13.224197,"marketCap":1469138999},{"date":"2024-05-24","current":14.166489,"twenty":4.4563,"median":8.734756,"eighty":13.241384,"marketCap":1510303519},{"date":"2024-05-31","current":14.905887,"twenty":4.4563,"median":8.734756,"eighty":13.248042,"marketCap":1589131510},{"date":"2024-06-07","current":15.724962,"twenty":4.4563,"median":8.734756,"eighty":13.254699,"marketCap":1676453895},{"date":"2024-06-14","current":15.619789,"twenty":4.452456,"median":8.72747,"eighty":13.254699,"marketCap":1665241293},{"date":"2024-06-21","current":14.485195,"twenty":4.448612,"median":8.720183,"eighty":13.254699,"marketCap":1544281101},{"date":"2024-06-28","current":14.60949,"twenty":4.437079,"median":8.698559,"eighty":13.248042,"marketCap":1557532358},{"date":"2024-07-05","current":14.552123,"twenty":4.437079,"median":8.698559,"eighty":13.254699,"marketCap":1551416394},{"date":"2024-07-12","current":13.854157,"twenty":4.437079,"median":8.698559,"eighty":13.254699,"marketCap":1477005489},{"date":"2024-07-15","current":13.586443,"twenty":4.437079,"median":8.698559,"eighty":13.254699,"marketCap":1448464320},{"date":"2024-08-02","current":13.149816,"twenty":4.293661,"median":8.639313,"eighty":12.179123,"marketCap":1401915033},{"date":"2024-08-09","current":12.65362,"twenty":4.293661,"median":8.639313,"eighty":12.333841,"marketCap":1357404400},{"date":"2024-08-16","current":12.71449,"twenty":4.293661,"median":8.639313,"eighty":12.422884,"marketCap":1363934183},{"date":"2024-08-23","current":13.275377,"twenty":4.293661,"median":8.639313,"eighty":12.626454,"marketCap":1424102779},{"date":"2024-08-30","current":14.261656,"twenty":4.293661,"median":8.639313,"eighty":13.112996,"marketCap":1529904861},{"date":"2024-09-06","current":13.281679,"twenty":4.293661,"median":8.639313,"eighty":13.211726,"marketCap":1424778831},{"date":"2024-09-13","current":13.861472,"twenty":4.293661,"median":8.639313,"eighty":13.294349,"marketCap":1486975582},{"date":"2024-09-20","current":13.839415,"twenty":4.293661,"median":8.639313,"eighty":13.376841,"marketCap":1484609401},{"date":"2024-09-27","current":14.00327,"twenty":4.293661,"median":8.639313,"eighty":13.543138,"marketCap":1502186744},{"date":"2024-10-04","current":14.854053,"twenty":4.293661,"median":8.639313,"eighty":13.653503,"marketCap":1593453715},{"date":"2024-10-11","current":14.854053,"twenty":4.293661,"median":8.639313,"eighty":13.84826,"marketCap":1593453715},{"date":"2024-10-18","current":14.737464,"twenty":4.293661,"median":8.639313,"eighty":13.994199,"marketCap":1580946760},{"date":"2024-10-25","current":15.008455,"twenty":4.293661,"median":8.639313,"eighty":14.123548,"marketCap":1610016980},{"date":"2024-10-31","current":14.655537,"twenty":4.293661,"median":8.639313,"eighty":14.202306,"marketCap":1572158088},{"date":"2024-11-08","current":15.118742,"twenty":4.28479,"median":8.64118,"eighty":14.37096,"marketCap":1621847884},{"date":"2024-11-15","current":13.409306,"twenty":4.28479,"median":8.692753,"eighty":14.37096,"marketCap":1673883715},{"date":"2024-11-22","current":14.009118,"twenty":4.28479,"median":8.746428,"eighty":14.37096,"marketCap":1748758223},{"date":"2024-11-29","current":15.251971,"twenty":4.28479,"median":8.78252,"eighty":14.384136,"marketCap":1903903601},{"date":"2024-12-06","current":15.416785,"twenty":4.28479,"median":8.81344,"eighty":14.484602,"marketCap":1924477227},{"date":"2024-12-13","current":14.881817,"twenty":4.28479,"median":8.908125,"eighty":14.552123,"marketCap":1857697260},{"date":"2024-12-20","current":12.709526,"twenty":4.28479,"median":8.950817,"eighty":14.552123,"marketCap":1586530122},{"date":"2024-12-27","current":12.995923,"twenty":4.28479,"median":9.012663,"eighty":14.552123,"marketCap":1622281013},{"date":"2025-01-03","current":12.674402,"twenty":4.28479,"median":9.065008,"eighty":14.552123,"marketCap":1582145578},{"date":"2025-01-10","current":12.901358,"twenty":4.275919,"median":9.188137,"eighty":14.552123,"marketCap":1610476474},{"date":"2025-01-17","current":14.179335,"twenty":4.275919,"median":9.277741,"eighty":14.552123,"marketCap":1770006394},{"date":"2025-01-24","current":13.960485,"twenty":4.275919,"median":9.31881,"eighty":14.552123,"marketCap":1742687317},{"date":"2025-01-31","current":15.316816,"twenty":4.275919,"median":9.382279,"eighty":14.568402,"marketCap":1911998142},{"date":"2025-02-07","current":15.738305,"twenty":4.275919,"median":9.466344,"eighty":14.652386,"marketCap":1964612662},{"date":"2025-02-14","current":15.435698,"twenty":4.275919,"median":9.483084,"eighty":14.687048,"marketCap":1926838135},{"date":"2025-02-21","current":16.178708,"twenty":4.275919,"median":9.514397,"eighty":14.715407,"marketCap":2019588089},{"date":"2025-02-28","current":15.284394,"twenty":4.275919,"median":9.568033,"eighty":14.816241,"marketCap":1907950871},{"date":"2025-03-07","current":19.286086,"twenty":4.270877,"median":9.582779,"eighty":14.884457,"marketCap":1781050742},{"date":"2025-03-14","current":19.942323,"twenty":4.270877,"median":9.582779,"eighty":14.985042,"marketCap":1841653603},{"date":"2025-03-21","current":19.862116,"twenty":4.270877,"median":9.595365,"eighty":15.085182,"marketCap":1834246586},{"date":"2025-03-28","current":19.719932,"twenty":4.270877,"median":9.649313,"eighty":15.125044,"marketCap":1821115967},{"date":"2025-04-04","current":20.186589,"twenty":4.270877,"median":9.689317,"eighty":15.233006,"marketCap":1864211334},{"date":"2025-04-11","current":16.708531,"twenty":4.275919,"median":9.707094,"eighty":15.273586,"marketCap":1543016172},{"date":"2025-04-17","current":18.524121,"twenty":4.275919,"median":9.710303,"eighty":15.333027,"marketCap":1710684087},{"date":"2025-04-21","current":18.509538,"twenty":4.270877,"median":9.726256,"eighty":15.350956,"marketCap":1709337357}],"updateTime":1745320798518}}}